Natural Killer T-Cell

The FDA cleared an investigational new drug application for AgenT-797 for the treatment of patients with COVID-19 infection, according to the agent’s manufacturer.

A modified natural killer T-cell therapy expressing a chimeric antigen receptor and interleukin-15 appeared feasible and safe for children with neuroblastoma, according to interim results of a first-in-human phase 1 trial presented at the virtual American Society of Gene and Cell Therapy Annual Meeting.

Green Cross LabCell, a South Korea-based biopharmaceutical company, announced it will begin development of a COVID-19 treatment based on its anticancer therapy work using natural killer cells.